in Vivo Toxicology Market Report 2025

The in-vivo toxicology market size has grown strongly in recent years. It will grow from $5.24 billion in 2024 to $5.61 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historical period can be attributed to the increasing demand for GLP-compliant studies, broader regulatory requirements, the rise of biologics and biosimilars needing safety evaluations, greater investment in oncology drug development, and the expansion of gene and cell therapy pipelines.

The in-vivo toxicology market size is expected to see strong growth in the next few years. It will grow to $7.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The projected growth in the forecast period can be attributed to increasing global drug development activities, a growing demand for personalized medicine, a rise in clinical trials, greater outsourcing of toxicology testing by pharmaceutical companies, and heightened concerns about consumer safety in food and personal care products. Key trends expected during this time include the creation of advanced animal models, the integration of imaging technologies with in vivo studies, the emergence of automated data collection systems, the adoption of AI and machine learning in toxicology data analysis, and innovations in telemetry and biomarker detection in animals.

The growing number of drug discoveries is expected to drive the expansion of the in vivo toxicology market in the coming years. Drug discovery involves the scientific process of identifying and designing new compounds that could serve as treatments or preventive measures for various diseases. Advances in biotechnology have significantly accelerated this process by improving the understanding of disease mechanisms and enabling the development of more targeted therapies. In vivo toxicology plays a crucial role in drug discovery by assessing the safety, tolerability, and potential adverse effects of investigational compounds within whole organisms. It helps detect dose-limiting toxicities and guides formulation and dosing decisions before clinical trials begin. For example, an article published by the Government of Canada in May 2025 reported that the number of medicines in clinical development worldwide reached 10,134 in March 2025, reflecting a 20% increase since September 2021. Consequently, the rising number of drug discoveries is fueling the growth of the in vivo toxicology market.

Key players in the in vivo toxicology market are concentrating on developing advanced technologies like secure cloud-based real-time data platforms to improve study management and accelerate decision-making. These platforms allow researchers and clients to securely access toxicology study data, milestones, planning tools, and documents remotely, fostering enhanced collaboration and transparency. For instance, in March 2023, Charles River Laboratories International Inc., a U.S.-based contract research organization, launched Apollo, a secure cloud-based platform designed to provide real-time access to toxicology study data. Apollo supports in vivo general toxicology studies with features for data visualization, planning, and milestone tracking. By offering immediate access to critical study information, it facilitates faster and more informed decisions, while also streamlining project planning and budget forecasting throughout drug development. Digitizing toxicology workflows with Apollo improves accuracy, efficiency, and teamwork in in vivo research.

In January 2022, Inotiv Inc., a U.S.-based contract research organization, acquired Integrated Laboratory Systems LLC for $56 million. This acquisition enabled Inotiv to expand its safety assessment capabilities by incorporating ILS’s expertise in toxicology and molecular biology. It also enhanced Inotiv’s proficiency in genomics, bioinformatics, and pathology, creating new opportunities to provide complementary drug development services. Integrated Laboratory Systems LLC is a U.S.-based provider specializing in in vivo toxicology services.

Major players in the in vivo toxicology market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings (Labcorp), Sigma-Aldrich Co. LLC, Eurofins Scientific SE, SGS Société Générale de Surveillance SA, Agilent Technologies Inc., WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Jubilant Life Sciences Limited, Evotec SE, The Jackson Laboratory, Inotiv Inc., SRI International, MatTek Corporation, Transcure Bioservices Pvt. Ltd., and Altogen Labs.

North America was the largest region in the in-vivo toxicology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in in vivo toxicology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the in vivo toxicology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in vivo toxicology market consists of revenues earned by entities by providing services such as neurotoxicity assessment, dermal toxicity testing, ocular toxicity testing, and local tolerance testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The in vivo toxicology market also includes sales of anesthesia systems, telemetry devices, blood collection and sampling tools, drug delivery systems, and environmental control equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The in vivo toxicology market research report is one of a series of new reports that provides in vivo toxicology market statistics, including in vivo toxicology industry global market size, regional shares, competitors with a in vivo toxicology market share, detailed in vivo toxicology market segments, market trends and opportunities, and any further data you may need to thrive in the in vivo toxicology industry. This in vivo toxicology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

In vivo toxicology is a field within toxicological science that examines the effects of chemical, biological, or physical agents on living organisms under controlled conditions. This method emphasizes studying how substances interact with complex biological systems, allowing for the evaluation of physiological, biochemical, and behavioral changes in whole organisms.

The primary products in in vivo toxicology include consumables and instruments. Consumables consist of materials like reagents, animal feed, and sample containers used during live organism experiments to evaluate the safety or toxicity of substances. The testing types encompass chronic, sub-chronic, sub-acute, and acute toxicity assessments, utilizing various methodologies such as in vivo animal models, genetically modified organisms, non-human primate studies, rodent models, and larger mammals. These tests are applied for evaluating immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental and reproductive toxicity (DART), among others, and are employed by end-users including pharmaceutical companies, biosimilars manufacturers, contract research organizations (CROs), academic and research institutions, and biotechnology firms.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.